Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Recursion Pharmaceuticals, Inc. - Class A Common Stock (NQ:RXRX)

3.265 -0.105 (-3.12%)
Streaming Delayed Price Updated: 3:00 PM EDT, Mar 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 7,509,996
Open 3.350
Bid (Size) 3.260 (12,500)
Ask (Size) 3.270 (19,500)
Prev. Close 3.370
Today's Range 3.250 - 3.420
52wk Range 2.980 - 7.180
Shares Outstanding 168,425,907
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Can This AI Stock Bounce Back in 2026? ↗
It's not looking too good for the biotech. 
Via The Motley Fool
Topics Animal Testing Artificial Intelligence
News headline image
Stocks Under $5 to Watch Now: LRMR, RXRX, NDRA, BTQ, CDIO Watch Now!
Via AB Newswire
Topics Artificial Intelligence Intellectual Property

Performance

YTD
-22.3%
-22.3%
1 Month
-5.6%
-5.6%
3 Month
-26.5%
-26.5%
6 Month
-33.6%
-33.6%
1 Year
-50.4%
-50.4%

More News

Read More
News headline image
Recursion (RXRX) Q4 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Artificial Intelligence Earnings
Recursion Pharmaceuticals (NASDAQ:RXRX) Soars on Q4 Earnings Beat ↗
Via Chartmill
News headline image
What's Behind The Jump In Recursion Pharmaceuticals Stock? ↗
Via Benzinga
News headline image
RXRX Stock Soars Pre-Market On Q4 Beat, Recursion CEO Says Company Has ‘Reached An Inflection Point’ ↗
Via Stocktwits
Topics Artificial Intelligence
News headline image
Recursion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Recursion To Be Featured in HighRes’ Lightning Talk at NVIDIA GTC
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Recursion to Participate in Upcoming Investor Conferences
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought ↗
Via The Motley Fool
Topics Artificial Intelligence
News headline image
NVIDIA’s 13F Bombshell: A New AI Power Trio Emerges ↗
Via MarketBeat
Topics Artificial Intelligence
News headline image
Recursion Pharmaceuticals Stock Drops: What's Behind It? ↗
Via Benzinga
News headline image
Recursion to Report Fourth Quarter and Full Year 2025 Business Updates and Financial Results on February 25
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
The Biotechnology Renaissance: AI and Capital Collide in a Multi-Trillion Dollar Pivot
Via MarketMinute
Topics Artificial Intelligence Economy Initial Public Offering
News headline image
Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
This $4 Stock Could Be Your Ticket to Millionaire Status ↗
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Harvard’s PopEVE AI Cracks the Code of Rare Diseases: Ending the ‘Diagnostic Odyssey’ for Millions
Via TokenRing AI
Topics Artificial Intelligence
News headline image
AI’s ‘Penicillin Moment’: How Generative Models Are Slashing Decades of Antibiotic Research into Months
Via TokenRing AI
Topics Artificial Intelligence
News headline image
Forget 2025: These 2 Growth Stocks Could Soar in 2026 ↗
Via The Motley Fool
News headline image
Can This Beaten-Down AI Stock Bounce Back in 2026? ↗
Via The Motley Fool
Topics Artificial Intelligence
News headline image
2 AI Stocks to Buy in 2026, and 1 to Avoid ↗
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Beyond the Protein: How AlphaFold 3 Redefined the Blueprint of Life and Accelerated the Drug Discovery Revolution
Via TokenRing AI
Topics Artificial Intelligence
News headline image
From Silicon to Syringes: Nvidia’s AI Dominance Solidified Through Landmark Eli Lilly Alliance
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Recursion to Present at 44th Annual J.P. Morgan Healthcare Conference
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
The $3 Billion Bet: How Isomorphic Labs is Rewriting the Rules of Drug Discovery with Eli Lilly and Novartis
Via TokenRing AI
Topics Artificial Intelligence

Frequently Asked Questions

Is Recursion Pharmaceuticals, Inc. - Class A Common Stock publicly traded?
Yes, Recursion Pharmaceuticals, Inc. - Class A Common Stock is publicly traded.
What exchange does Recursion Pharmaceuticals, Inc. - Class A Common Stock trade on?
Recursion Pharmaceuticals, Inc. - Class A Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Recursion Pharmaceuticals, Inc. - Class A Common Stock?
The ticker symbol for Recursion Pharmaceuticals, Inc. - Class A Common Stock is RXRX on the Nasdaq Stock Market
What is the current price of Recursion Pharmaceuticals, Inc. - Class A Common Stock?
The current price of Recursion Pharmaceuticals, Inc. - Class A Common Stock is 3.265
When was Recursion Pharmaceuticals, Inc. - Class A Common Stock last traded?
The last trade of Recursion Pharmaceuticals, Inc. - Class A Common Stock was at 03/20/26 03:00 PM ET
What is the market capitalization of Recursion Pharmaceuticals, Inc. - Class A Common Stock?
The market capitalization of Recursion Pharmaceuticals, Inc. - Class A Common Stock is 549.91M
How many shares of Recursion Pharmaceuticals, Inc. - Class A Common Stock are outstanding?
Recursion Pharmaceuticals, Inc. - Class A Common Stock has 550M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.